Transcarent completed its acquisition of Accolade on April 8, 2025, after announcing the agreement on January 8. Accolade shareholders were entitled to $7.03 in cash per share, and Accolade became an indirect wholly owned subsidiary of privately held Transcarent. The roughly $621 million headline value is described differently across transaction materials, so it should not be treated as a single unqualified measure.
What was the Accolade purchase price?
The agreed consideration was $7.03 in cash per Accolade share, subject to customary exceptions and applicable withholding. Transcarent described the transaction at announcement as approximately $621 million in total equity value. An SEC-filed communication describes the amount as including Accolade’s net debt, while Oregon’s review report also calls it total equity value. Those labels are not interchangeable, so the headline figure is best presented with attribution rather than as a definitive enterprise-value measure. Transcarent’s January 8 announcement and the SEC-filed transaction communication document the terms.
The announcement materials also cite an approximately 110% premium, but they use different comparison dates: Transcarent’s release compares with January 7, 2025, while the SEC-filed communication uses January 8, the last trading day before public disclosure. Without reconciling that difference against definitive proxy materials and contemporaneous market data, the premium is not a settled figure to repeat without qualification.
When did the deal close, and what changed?
The agreement was signed and announced on January 8, 2025; the merger closed on April 8, 2025, after required approvals and closing conditions. Signing marked the agreement, not the transfer of ownership. At closing, merger subsidiary Acorn Merger Sub merged into Accolade, which survived as an indirect wholly owned subsidiary of Transcarent. Accolade shares were converted into the right to receive the cash consideration, and Accolade notified Nasdaq and requested that its common stock be removed from listing. The Accolade Form 8-K records the closing mechanics.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
Transcarent said the transaction received the necessary regulatory and shareholder approvals and that Accolade had joined a privately held company. Its April 8 closing announcement said financing included General Catalyst and Glen Tullman’s 62 Ventures, existing and new investors, combined-company cash, and debt financing led by J.P. Morgan.
Why did Transcarent want Accolade?
The companies’ stated rationale was to bring together services that help people navigate benefits and obtain care. Transcarent described its offering as including AI-powered WayFinding, pharmacy benefits, and care experiences in cancer, surgery, and weight health. Accolade’s offering included personalized healthcare navigation, advocacy, expert medical opinions, and primary care. The intended combination was broader service coverage for employers and health plans, rather than a consumer-facing purchase of a single product. These are company descriptions of the strategy, not proof that the combined organization has delivered better health outcomes or lower costs.
Rank #2
- The 2024 ERG guide helps satisfy 49 CFR 172.602 DOT requirement. This requirement states that hazmat shipments be accompanied by emergency response info.
- Pocketbook aids in emergency preparedness, planning, and training with ERGs numerically indexed and color-coded to help emergency responders find vital information fast.
- 2024 Updates: The Pipeline and Hazardous Materials Safety Administration (PHMSA) released a comprehensive summary of updates. Most significantly a QR code on the back cover that provides access to critical incident reporting information.
- Other changes for 2024 have been made to continue to provide the most accurate emergency response information to help all front-line persons and all first responders stay safe during transportation emergencies.
- Specifications: 4" x 5 1/2" Pocketbook Size, English, Spiralbound. Copyright 2024.
What scale did the combined company report?
At closing, Transcarent reported that the combined organization served more than 20 million members and more than 1,700 employer and health-plan clients. These are figures from Transcarent’s April 8, 2025 announcement; they are company-reported and dated, not independently audited figures or a claim about the organization’s current scale.
What did Oregon’s review find?
The Oregon Health Authority’s transaction-specific review provides a view of the deal’s potential effects in that state, not a universal assessment of the combined company or a substitute for all other approvals. OHA accepted Transcarent’s complete notice on March 6, 2025, conducted a 30-day preliminary review of cost, access, quality, and equity, and approved the transaction on April 7. It received no public comments and reported no specific concerns about reduced access, higher costs, lower quality, or adverse equity effects; it concluded that a comprehensive review was unwarranted given the transaction’s size and effects. The agency’s preliminary review report and final order describe the process and findings. The final order says the agency relied on information in the parties’ notice and that the transaction involved no health providers physically located in Oregon and did not affect in-person care options there.
Free tools Windows power users keep installed
One-click scans. No signup required.
Rank #3
What the acquisition does—and does not—establish
The acquisition changed Accolade’s ownership and placed its services within Transcarent’s broader benefits and care platform. Transcarent presented the combination as a way to make healthcare easier to navigate and more affordable. The reviewed transaction materials do not establish realized post-merger savings, improved clinical outcomes, or integration success as measured results. Those remain distinct from the stated strategic rationale and reported customer scale.
Quick Recap
Best Value
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
